NEW YORK, NY--(Marketwire -10/20/11)- IntelliCell BioSciences, Inc. (OTCQB: SVFC.PK - News) (Pinksheets: SVFC.PK - News) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today a study published regarding the efficacy of IntelliCell's proprietary SVF in the treatment of gum recession.
The pilot study, published in the October 2011 edition of The Journal of Implant & Advanced Clinical Dentistry, is authored by Nicholas Toscano, DDS, MS, Danny Holtzclaw, DDS, MS, and Steven Victor, MD.
The pilot study, which was a single center study that included 7 female and one male patient ranging from 23 to 45 years of age with gingival recession, showed that Mucograft® collagen matrix combined with SVF treatments may be a viable and advantageous alternative to treating gum recession and potentially eliminate the need for invasive harvesting of gum tissue. By the end of the six-month prospective study, the mean increase in root coverage was 87% for the patients treated. Sixty-six percent of treated patients achieved 100% root coverage. These numbers indicate that gum recession was reversed, with gum tissue growing back over the root area. This was achieved without having to transplant tissue from another part of the mouth into the gum line. Post-treatment, patients reported little or no pain and swelling.
"This is a very encouraging study. Gingival recession is a significant issue in dentistry and IntelliCell is offering a new, potentially superior, non-invasive solution that minimizes patient discomfort and improves outcomes. Dentistry is one of numerous fields in which our SVF may show efficacy," stated IntelliCell Chairman and CEO, Dr. Steven Victor. "This clearly exhibits the potential functionality of the cells contained in the SVF we manufacture using our proprietary process. We intend to seek out opportunities to conduct clinical research and publish in peer reviewed journals in order to quantify the efficacy results of SVF across multiple medical disciplines."
"I am really excited about stromal vascular fracture stem cells and the impact on regenerative dentistry. Future research could prove this to be a major breakthrough in oral and maxillofacial reconstruction," stated Dr. Nicholas Toscano, the periodontist who ran the study.
According to information posted on a website maintained by Photopharmica, the market for the treatment of periodontal disease reached $6 billion in 2000. The information further states that, "Periodontal disease is the most prevalent disease in humans -- more prevalent than heart disease. Degenerative periodontal disease affects 20+% of the population over age 50."
The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.
About IntelliCell Biosciences, Inc.
IntelliCell is a pioneering regenerative medicine company focused on the expanding regenerative medical markets using stromal vascular fraction derived from adult adipose tissue. IntelliCell intends to initially focus on setting up tissue processing centers throughout the United States with managing partners. The centers will receive and employ the IntelliCell™ process to the adipose stromal vascular fraction harvested by physicians in their own offices, and then return the IntelliCells™ to the physicians the same day labeled "autologous homologous." IntelliCell has already established processing centers in Baton Rouge, New York City, Philadelphia, Dallas/Ft. Worth, Denver, Houston, New Orleans, Orlando, and West Palm Beach. In the future, IntelliCell intends to pursue expansion to secondary markets and beyond the U.S. through a combination of company-owned and licensed clinical facilities. For additional information, visit http://www.intellicellbiosciences.com or call 212 249 3050.
Certain statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.